Organometallic Ligands

Erlotinib is a drug that is used to treat human malignancies. It is a type of kinase inhibitor that inhibits the EGFR tyrosine kinase, preventing the activation of downstream signalling pathways. Erlotinib has been shown to be effective in treating squamous cell carcinoma, melanoma, and other types of skin cancer. Additionally, Erlotinib has potential for use as an anti-inflammatory agent in the treatment of psoriasis and ulcerative colitis. Erlotinib hydrochloride is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

KT-474 is an oral small molecule protein degrader, which is derived from targeted protein degradation technology. This compound functions as an investigational agent specifically designed to degrade IRAK4, a key kinase involved in the signaling pathways of pro-inflammatory cytokines such as IL-1 and IL-18, which are crucial in the regulation of innate and adaptive immunity. The mode of action is based on hijacking the cell's ubiquitin-proteasome system to selectively bind to and degrade IRAK4, thereby reducing inflammation at the molecular level. The primary applications of KT-474 are in the treatment of autoimmune and inflammatory diseases where IRAK4 plays a pivotal role. By selectively targeting and degrading IRAK4, KT-474 presents a novel approach to modulating immune responses, potentially addressing conditions such as rheumatoid arthritis, systemic lupus erythematosus, and other chronic inflammatory disorders. Its development represents an advancement in therapeutic strategies aiming to provide precision medicine solutions by manipulating the protein homeostasis within cells. This approach underscores the potential of targeted protein degradation as a versatile and effective modality in therapeutic contexts.

Ibedenone is an analogue of ubiquinone that is used to treat visual impairment in patients with Leber’s Hereditary Optic Neuropathy. It is also known as an analogue of Coenzyme Q10. It has antioxidant properties. This drug increases ATP production that’s needed for mitochondrial function and reduces free radicals. It also protects the lipid membrane and mitochondria from oxidative damage. Idebenone is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Inhibitor of glycogen phosphorylase and alpha-glucosidases

Aldi-2 is a cutting-edge CRISPR-based gene editing tool, which is an engineered ribonucleoprotein complex derived from the Streptococcus pyogenes bacterial immune system. The system operates through the formation of a complex between a guide RNA (gRNA) and the Cas9 protein, facilitating targeted double-strand breaks in DNA sequences. This mode of action relies on the gRNA to provide specificity, directing the Cas9 enzyme to a complementary DNA sequence in the genome, where it induces a precise cut. Aldi-2 is primarily used in genomic research applications, where it is employed to investigate gene function, create knockout models, and study disease mechanisms. Its applications extend to potential therapeutic uses, such as correcting genetic mutations associated with monogenic disorders. In agricultural biotechnology, Aldi-2's ability to enhance crop traits through targeted gene modification is also actively being explored. By enabling high-precision genetic surgeries, Aldi-2 represents a powerful tool for advancing our understanding of genetics and developing targeted interventions across multiple scientific domains.

Uricosuric agent

PB 28 dihydrochloride is a selective sigma-2 receptor ligand, which is a synthetic compound targeting specific receptor sites. These receptors are predominantly found in cancer cells, implicating them in cellular proliferation and apoptosis. PB 28 dihydrochloride is synthetically derived and is employed extensively in preclinical studies. Its mode of action involves high-affinity binding to the sigma-2 receptors, allowing modulation of cellular stress responses and apoptosis pathways. Predominantly utilized in oncology research, PB 28 dihydrochloride provides valuable insights into cancer biology. By influencing cancer cell viability, it aids in the understanding of tumor progression and offers potential as a therapeutic lead. Additionally, it facilitates the investigation of sigma receptor functions and their role in various physiological processes. Such studies are foundational in developing novel therapeutic strategies targeting cancer and other diseases characterized by abnormal cell growth and division.

Vitamin B3; antioxidant; favours cell repair

Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes. Sorafenib is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

K 114 is a selective herbicide, which is a synthetic chemical intervention designed to target and manage unwanted plant species in agricultural settings. Derived from advanced chemical synthesis processes, it ensures high purity and efficacy in real-world applications. The mode of action involves the inhibition of key enzymatic pathways crucial for the survival and growth of broadleaf and grassy weeds, thereby effectively hindering their development without affecting the desired crops. The primary uses and applications of K 114 are in controlling a variety of weeds in diverse cropping systems such as maize, soybeans, and wheat. Its selectivity allows for targeted action, minimizing damage to the crops and preserving yield potential. Researchers and practitioners in agronomy and crop protection will find K 114 particularly valuable in integrated weed management programs, where it can be combined with other cultural and chemical practices to sustain agricultural productivity and mitigate resistance development in weed populations.

SM-276001 is a selective androgen receptor modulator (SARM), which is a non-steroidal compound derived from an extensive process of chemical synthesis focused on creating receptor-specific agonists. Designed to bind selectively to androgen receptors, its mode of action leverages differential tissue selectivity, aiming to stimulate anabolic activity in muscle and bone while minimizing androgenic effects in other tissues. This selectivity is achieved by modulating receptor configurations to induce distinct transcriptional pathways compared to traditional anabolic steroids. The applications of SM-276001 are primarily within the realm of potentially treating muscle wasting conditions, osteoporosis, and age-related muscle degeneration. By targeting specific androgen receptors, it may enhance muscle and bone growth without exerting significant impact on prostate or cardiac tissues, which remains a substantial concern with other androgen-based therapies. This tissue-selective action is of particular interest in both clinical and experimental settings, where precise modulation of anabolic effects is desired. Further research into its pharmacokinetics and long-term effects continues to be a significant focus within the scientific community, given its promising therapeutic potential.

Antagonist of proto-oncogene MDM2 and its interaction with p53

Cyjohnphos hbf4 is a research tool that binds to an ion channel and blocks its activity. Cyjohnphos hbf4 has been shown to be an activator of the ligand-gated ion channels, such as nicotinic acetylcholine receptor and GABA receptors. This compound also binds to the GABAA receptor, which is responsible for regulating synaptic transmission in the brain. Cyjohnphos hbf4 has been shown to inhibit the activity of potassium channels in a voltage-dependent manner. It does not affect calcium or sodium channels. Cyjohnphos hbf4 has been used as an inhibitor of peptide binding in cell biology experiments and as a pharmacological tool when studying protein interactions.

Opioid receptor antagonist

Please enquire for more information about Siltenzepine including the price, delivery time and more detailed product information at the technical inquiry form on this page

RK-33 is a small molecule inhibitor, which is synthesized as a chemical compound. It functions by targeting and inhibiting the activity of DDX3, a DEAD-box RNA helicase, which plays a crucial role in the modulation of RNA biogenesis and translation processes. By interfering with DDX3, RK-33 disrupts processes essential for the proliferation of certain cancer cells, making it a significant focus in cancer research. The compound demonstrates potential therapeutic applications in oncology, particularly in the treatment of cancers showing elevated DDX3 activity. Studies have shown its ability to impede the growth of tumor cells in various cancer models, highlighting its role in enhancing the efficacy of existing therapeutic strategies. Researchers are keenly investigating RK-33's effectiveness in combination therapies to better understand its potential in reducing tumor resistance and improving treatment outcomes. Such investigations could pave the way for developing targeted therapies across diverse types of malignancies where DDX3 is a pivotal factor.

ÎŽ opioid receptor agonist; anti-nociceptive; anti-depressant

Bendamustine is a bifunctional mechlorethamine derivative with alkylator and antimetabolite properties. An alkylating group, a benzimidazole ring that may function as a purine analog, and a butyric acid side chain are the three active moieties found in bendamustine. Through its function as an alkylating agent, Bendamustine causes intra and inter-strand crosslinks between DNA bases resulting in DNA, RNA synthesis inhibition and cell death. Bendamustine HCl is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Elesclomol is an investigational anticancer agent, which is a small-molecule compound. It functions by targeting the cellular oxidative stress pathway; specifically, it enhances the production of reactive oxygen species (ROS) within cancer cells. By elevating ROS levels beyond the threshold tolerable by cancer cells, Elesclomol induces apoptosis through the disruption of mitochondrial function, making it selective for environments with heightened oxidative stress. Originally sourced from proprietary chemical libraries and identified through its potent cytotoxic effects in vitro, Elesclomol's mechanism leverages the inherent oxidative susceptibility of certain cancer phenotypes. Its primary action involves the transfer of electrons from ferrous ions, leading to the disproportionate accumulation of ROS, disturbing the delicate redox balance essential for cancer cell survival. Elesclomol has been studied in combination with other chemotherapeutic agents and has shown potential in treating various malignancies, particularly melanoma and other cancers characterized by increased oxidative stress. Despite its promise, further investigation is warranted to fully elucidate its therapeutic index and integration into oncological treatment regimens.

Losmiprofen is a non-steroidal anti-inflammatory drug (NSAID) synthesized through pharmaceutical chemical processes. It is structurally designed to inhibit cyclooxygenase (COX) enzymes, which play a key role in the conversion of arachidonic acid to prostaglandins. Prostaglandins are lipid compounds that exacerbate inflammation, pain, and fever. By selectively acting on the COX enzymes, losmiprofen mitigates the synthesis of these mediators, thereby reducing inflammatory responses. The primary clinical applications of losmiprofen include the management of various types of pain and inflammatory conditions. This encompasses its use in alleviating symptoms of osteoarthritis, rheumatoid arthritis, and other musculoskeletal disorders. Its efficacy in managing post-operative pain has also been documented, making it a versatile agent in pain management protocols. The pharmacokinetic profile of losmiprofen facilitates a controlled modulation of inflammatory processes, leading to improved patient outcomes with minimized side effects. Researchers continue to explore its therapeutic potential and optimize its clinical implementation, highlighting the drug's significance in the field of anti-inflammatory pharmacotherapy.